Histone deacetylase-3 interacts with ataxin-7 and is altered in a spinocerebellar ataxia type 7 mouse model

Molecular Neurodegeneration

Volumn 8, Issue 1, 2013, Pages

  Duncan, Carlotta E ^a   An, Mahru C ^a   Papanikolaou, Theodora ^a   Rugani, Caitlin ^a   Vitelli, Cathy ^a   Ellerby, Lisa M ^a  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

Ataxin 7; HDAC; Polyglutamine; Spinocerebellar ataxia type 7

Indexed keywords

ATAXIN 7; HISTONE DEACETYLASE 3; LYSINE; POLYGLUTAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBELLUM; CONTROLLED STUDY; GLIA; HISTONE ACETYLATION; MOUSE; MUTATION; NERVE CELL; NEUROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PROCESSING; SPINOCEREBELLAR TRACT;

MUS; MUS MUSCULUS;

ANIMALS; BLOTTING, WESTERN; BRAIN; DISEASE MODELS, ANIMAL; HEK293 CELLS; HISTONE DEACETYLASES; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SPINOCEREBELLAR ATAXIAS; TRANSFECTION;

EID: 84886126273     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-8-42     Document Type: Article

References (49)

1. An expanded CAG repeat sequence in spinocerebellar ataxia type 7. Lindblad K, Savontaus ML, Stevanin G, Holmberg M, Digre K, Zander C, Ehrsson H, David G, Benomar A, Nikoskelainen E, Trottier Y, Holmgren G, Ptacek LJ, Anttinen A, Brice A, Schalling M, Genome Res 1996 6 965 971 10.1101/gr.6.10.965 8908515 (Pubitemid 26388088)
2. Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. David G, Abbas N, Stevanin G, Durr A, Yvert G, Cancel G, Weber C, Imbert G, Saudou F, Antoniou E, Drabkin H, Gemmill R, Giunti P, Benomar A, Wood N, Ruberg M, Agid Y, Mandel JL, Brice A, Nat Genet 1997 17 65 70 10.1038/ng0997-65 9288099 (Pubitemid 27377533)
3. Molecular genetic analysis of autosomal dominant cerebellar ataxia with retinal degeneration (ADCA type II) caused by CAG triplet repeat expansion. Del-Favero J, Krols L, Michalik A, Theuns J, Lofgren A, Goossens D, Wehnert A, Van den Bossche D, Van Zand K, Backhovens H, van Regenmorter N, Martin JJ, Van Broeckhoven C, Hum Mol Genet 1998 7 177 186 10.1093/hmg/7.2.177 9425224 (Pubitemid 28048532)
4. Molecular and clinical correlations in autosomal dominant cerebellar ataxia with progressive macular dystrophy (SCA7). David G, Durr A, Stevanin G, Cancel G, Abbas N, Benomar A, Belal S, Lebre AS, Abada-Bendib M, Grid D, Holmberg M, Yahyaoui M, Hentati F, Chkili T, Agid Y, Brice A, Hum Mol Genet 1998 7 165 170 10.1093/hmg/7.2.165 9425222 (Pubitemid 28048530)
5. Spinocerebellar ataxia type 7 associated with pigmentary retinal dystrophy. Michalik A, Martin JJ, Van Broeckhoven C, Eur J Hum Genet 2004 12 2 15 10.1038/sj.ejhg.5201108 14571264 (Pubitemid 38180965)
6. Distribution of ataxin-7 in normal human brain and retina. Cancel G, Duyckaerts C, Holmberg M, Zander C, Yvert G, Lebre AS, Ruberg M, Faucheux B, Agid Y, Hirsch E, Brice A, Brain 2000 123 Pt 12 2519 2530 11099453
7. Expression analysis of ataxin-7 mRNA and protein in human brain: evidence for a widespread distribution and focal protein accumulation. Lindenberg KS, Yvert G, Muller K, Landwehrmeyer GB, Brain Pathol 2000 10 385 394 10885657 (Pubitemid 30431291)
8. Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration. Palhan VB, Chen S, Peng GH, Tjernberg A, Gamper AM, Fan Y, Chait BT, La Spada AR, Roeder RG, Proc Natl Acad Sci USA 2005 102 8472 8477 10.1073/pnas.0503505102 15932940 (Pubitemid 40862760)
9. Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes. Helmlinger D, Hardy S, Sasorith S, Klein F, Robert F, Weber C, Miguet L, Potier N, Van-Dorsselaer A, Wurtz JM, Mandel JL, Tora L, Devys D, Hum Mol Genet 2004 13 1257 1265 10.1093/hmg/ddh139 15115762 (Pubitemid 38877879)
10. A role for both wild-type and expanded ataxin-7 in transcriptional regulation. Strom AL, Forsgren L, Holmberg M, Neurobiol Dis 2005 20 646 655 10.1016/j.nbd.2005.04.018 15936949 (Pubitemid 41619341)
11. Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Holmberg M, Duyckaerts C, Durr A, Cancel G, Gourfinkel-An I, Damier P, Faucheux B, Trottier Y, Hirsch EC, Agid Y, Brice A, Hum Mol Genet 1998 7 913 918 10.1093/hmg/7.5.913 9536097 (Pubitemid 28221256)
12. Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Einum DD, Townsend JJ, Ptacek LJ, Fu YH, Neurogenetics 2001 3 83 90 10.1007/s100480000100 11354830 (Pubitemid 33738398)
13. SCA7 mouse models show selective stabilization of mutant ataxin-7 and similar cellular responses in different neuronal cell types. Yvert G, Lindenberg KS, Devys D, Helmlinger D, Landwehrmeyer GB, Mandel JL, Hum Mol Genet 2001 10 1679 1692 10.1093/hmg/10.16.1679 11487572 (Pubitemid 32776298)
14. Polyglutamine-expanded ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse model of SCA7. La Spada AR, Fu Y, Sopher BL, Libby RT, Wang X, Li LY, Einum DD, Huang J, Possin DE, Smith AC, Martinez RA, Koszdin KL, Treuting PM, Ware CB, Hurley JB, Ptacek LJ, Chen S, Neuron 2001 31 913 927 10.1016/S0896-6273(01)00422-6 11580893 (Pubitemid 32925279)
15. A conditional pan-neuronal Drosophila model of spinocerebellar ataxia 7 with a reversible adult phenotype suitable for identifying modifier genes. Latouche M, Lasbleiz C, Martin E, Monnier V, Debeir T, Mouatt-Prigent A, Muriel MP, Morel L, Ruberg M, Brice A, Stevanin G, Tricoire H, J Neurosci 2007 27 2483 2492 10.1523/JNEUROSCI.5453-06.2007 17344386 (Pubitemid 46393606)
16. Posttranslational modification of ataxin-7 at lysine 257 prevents autophagy-mediated turnover of an N-terminal caspase-7 cleavage fragment. Mookerjee S, Papanikolaou T, Guyenet SJ, Sampath V, Lin A, Vitelli C, DeGiacomo F, Sopher BL, Chen SF, La Spada AR, Ellerby LM, J Neurosci 2009 29 15134 15144 10.1523/JNEUROSCI.4720-09.2009 19955365
17. Histone acetylation, acetyltransferases, and ataxia-alteration of histone acetylation and chromatin dynamics is implicated in the pathogenesis of polyglutamine-expansion disorders. McCullough SD, Grant PA, Adv Protein Chem Struct Biol 2010 79 165 203 20621284
18. Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptors. Tsai CC, Kao HY, Mitzutani A, Banayo E, Rajan H, McKeown M, Evans RM, Proc Natl Acad Sci USA 2004 101 4047 4052 10.1073/pnas.0400615101 15016912 (Pubitemid 38405881)
19. Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation. Evert BO, Araujo J, Vieira-Saecker AM, de Vos RA, Harendza S, Klockgether T, Wullner U, J Neurosci 2006 26 11474 11486 10.1523/JNEUROSCI.2053-06.2006 17079677 (Pubitemid 44772178)
20. Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. Li J, Wang J, Wang J, Nawaz Z, Liu JM, Qin J, Wong J, EMBO J 2000 19 4342 4350 10.1093/emboj/19.16.4342 10944117 (Pubitemid 30623745)
21. The histone deacetylase-3 complex contains nuclear receptor corepressors. Wen YD, Perissi V, Staszewski LM, Yang WM, Krones A, Glass CK, Rosenfeld MG, Seto E, Proc Natl Acad Sci USA 2000 97 7202 7207 10.1073/pnas.97.13.7202 10860984 (Pubitemid 30431441)
22. The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Guenther MG, Barak O, Lazar MA, Mol Cell Biol 2001 21 6091 6101 10.1128/MCB.21.18.6091-6101.2001 11509652 (Pubitemid 34263509)
23. Regulation of histone deacetylase activities. Sengupta N, Seto E, J Cell Biochem 2004 93 57 67 10.1002/jcb.20179 15352162
24. Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Baek SH, Ohgi KA, Rose DW, Koo EH, Glass CK, Rosenfeld MG, Cell 2002 110 55 67 10.1016/S0092-8674(02)00809-7 12150997 (Pubitemid 34874606)
25. Distribution of histone deacetylases 1-11 in the rat brain. Broide RS, Redwine JM, Aftahi N, Young W, Bloom FE, Winrow C, J Mol Neurosci 2007 31 47 58 10.1007/BF02686117 17416969 (Pubitemid 46588030)
26. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Bhaskara S, Chyla BJ, Amann JM, Knutson SK, Cortez D, Sun ZW, Hiebert SW, Mol Cell 2008 30 61 72 10.1016/j.molcel.2008.02. 030 18406327 (Pubitemid 351470157)
27. Selective toxicity by HDAC3 in neurons: regulation by Akt and GSK3beta. Bardai FH, D'Mello SR, J Neurosci 2011 31 1746 1751 10.1523/JNEUROSCI.5704-10. 2011 21289184
28. Histone deacetylase-1 (HDAC1) is a molecular switch between neuronal survival and death. Bardai FH, Price V, Zaayman M, Wang L, D'Mello SR, J Biol Chem 2012 287 35444 35453 10.1074/jbc.M112.394544 22918830
29. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PA, Steffan JS, Marsh JL, Thompson LM, Lewis CM, Marks PA, Bates GP, Proc Natl Acad Sci USA 2003 100 2041 2046 10.1073/pnas.0437870100 12576549 (Pubitemid 36254570)
30. Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity. Bates EA, Victor M, Jones AK, Shi Y, Hart AC, J Neurosci 2006 26 2830 2838 10.1523/JNEUROSCI.3344-05.2006 16525063 (Pubitemid 43357867)
31. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Thomas EA, Coppola G, Desplats PA, Tang B, Soragni E, Burnett R, Gao F, Fitzgerald KM, Borok JF, Herman D, Geschwind DH, Gottesfeld J, Proc Natl Acad Sci USA 2008 105 15564 15569 10.1073/pnas.0804249105 18829438
32. Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model. Sandi C, Pinto RM, Al-Mahdawi S, Ezzatizadeh V, Barnes G, Jones S, Rusche JR, Gottesfeld JM, Pook MA, Neurobiol Dis 2011 42 496 505 10.1016/j.nbd.2011.02.016 21397024
33. SUMOylation attenuates the aggregation propensity and cellular toxicity of the polyglutamine expanded ataxin-7. Janer A, Werner A, Takahashi-Fujigasaki J, Daret A, Fujigasaki H, Takada K, Duyckaerts C, Brice A, Dejean A, Sittler A, Hum Mol Genet 2010 19 181 195 10.1093/hmg/ddp478 19843541
34. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Butler R, Bates GP, Nature Rev Neurosci 2006 7 784 796 10.1038/nrn1989 (Pubitemid 44435261)
35. Histone deacetylase inhibitors reduce polyglutamine toxicity. McCampbell A, Taye AA, Whitty L, Penney E, Steffan JS, Fischbeck KH, Proc Natl Acad Sci USA 2001 98 15179 15184 10.1073/pnas.261400698 11742087 (Pubitemid 34013989)
36. Histone deacetylases: focus on the nervous system. Morrison BE, Majdzadeh N, D'Mello SR, Cellular and molecular life sciences: CMLS 2007 64 2258 2269 10.1007/s00018-007-7035-9 17530170 (Pubitemid 47347953)
37. HDAC inhibitors and neurodegeneration: at the edge between protection and damage. Dietz KC, Casaccia P, Pharmacological research: the official journal of the Italian Pharmacological Society 2010 62 11 17 10.1016/j.phrs.2010.01.011 20123018
38. HDAC3 is a critical negative regulator of long-term memory formation. McQuown SC, Barrett RM, Matheos DP, Post RJ, Rogge GA, Alenghat T, Mullican SE, Jones S, Rusche JR, Lazar MA, Wood MA, J Neurosci 2011 31 764 774 10.1523/JNEUROSCI.5052-10.2011 21228185
39. Histone modifications affect timing of oligodendrocyte progenitor differentiation in the developing rat brain. Shen S, Li J, Casaccia-Bonnefil P, J Cell Biol 2005 169 577 589 10.1083/jcb.200412101 15897262 (Pubitemid 41002851)
40. Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport. Custer SK, Garden GA, Gill N, Rueb U, Libby RT, Schultz C, Guyenet SJ, Deller T, Westrum LE, Sopher BL, La Spada AR, Nat Neurosci 2006 9 1302 1311 10.1038/nn1750 16936724 (Pubitemid 44454272)
41. Spinocerebellar ataxia type 7 cerebellar disease requires the coordinated action of mutant ataxin-7 in neurons and glia, and displays non-cell-autonomous bergmann glia degeneration. Furrer SA, Mohanachandran MS, Waldherr SM, Chang C, Damian VA, Sopher BL, Garden GA, La Spada AR, J Neurosci 2011 31 16269 16278 10.1523/JNEUROSCI.4000-11.2011 22072678
42. Genome-wide histone acetylation is altered in a transgenic mouse model of Huntington's disease. McFarland KN, Das S, Sun TT, Leyfer D, Xia E, Sangrey GR, Kuhn A, Luthi-Carter R, Clark TW, Sadri-Vakili G, Cha JH, PloS one 2012 7 41423 10.1371/journal.pone.0041423 22848491
43. Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing. Xu C, Soragni E, Chou CJ, Herman D, Plasterer HL, Rusch JR, Gottesfeld JM, Chem Biol 2009 16 980 989 10.1016/j.chembiol.2009.07.010 19778726
44. Effects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington's Disease. Chen JY, Wang E, Galvan L, Huynh M, Joshi P, Cepeda C, Levine MS, PLoS Currents 2013 5 http://currents.plos.org/hd/article/effects-of-the-pimelic-diphenylamide- histone-deacetylase-inhibitor-hdaci-4b-on-the-r62-and-n171-82q-mouse-models-of- huntingtons-disease/, doi:10.1371/currents.hd.ec3547da1c2a520ba959ee7bf8bdd202
45. Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo. Beconi M, Aziz O, Matthews K, Moumne L, O'Connell C, Yates D, Clifton S, Pett H, Vann J, Crowley L, Haughan AF, Smith DL, Woodman B, Bates GP, Brookfield F, Burli RW, McAllister G, Dominguez C, Munoz-Sanjuan I, Beaumont V, PloS One 2012 7 44498 10.1371/journal.pone.0044498 22973455
46. Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease. Moumne L, Campbell K, Howland D, Ouyang Y, Bates GP, PloS One 2012 7 31080 10.1371/journal.pone.0031080 22347433
47. Disassociation of histone deacetylase-3 from normal huntingtin underlies mutant huntingtin neurotoxicity. Bardai FH, Verma P, Smith C, Rawat V, Wang L, D'Mello SR, J Neurosci 2013 33 11833 11838 10.1523/JNEUROSCI.5831-12.2013 23864673
48. Histone deacetylase complexes promote trinucleotide repeat expansions. Debacker K, Frizzell A, Gleeson O, Kirkham-McCarthy L, Mertz T, Lahue RS, PLoS Biol 2012 10 1001257 10.1371/journal.pbio.1001257 22363205
49. Excessive HDAC activation is critical for neurodegeneration in the rd1 mouse. Sancho-Pelluz J, Alavi MV, Sahaboglu A, Kustermann S, Farinelli P, Azadi S, van Veen T, Romero FJ, Paquet-Durand F, Ekstrom P, Cell death Dis 2010 1 24 10.1038/cddis.2010.4 21364632